OREANDA-NEWS. April 20, 2012. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its 100 percent owned China subsidiary, Daiichi Sankyo (China) Holdings, Co., Ltd. (hereafter, Daiichi Sankyo China), came to an agreement with Shanghai Xinshengyuan Pharmaceutical (Group) Co., Ltd. (hereafter, Xinshengyuan Group)to receive all equity owned by Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., Ltd. (hereafter, Xinshengyuan), the 100 percent owned subsidiary of Xinshengyuan Group. The matter has been registered with the appropriate Chinese authorities.

Daiichi Sankyo established Daiichi Sankyo China in November 2011 for the purpose of advancing its strategic investment in China. With this agreement, all of the equity of Xinshengyuan will be transferred to a wholly-owned subsidiary of Daiichi Sankyo China.

By adding Xinshengyuan into the Group, Daiichi Sankyo will be able to import and market Ranbaxy products to China in addition to its own product lines. Furthermore, by adding innovative pharmaceuticals, including other company’s products, to generic pharmaceuticals in the future, Daiichi Sankyo aims to further grow its business in China.